


*Industry Supported Non-CE Presentation
from Sanofi Medical*



TARGETING IMMUNE NETWORK DYSREGULATION IN MS TO ADVANCE DISEASE MANAGEMENT



Wednesday, **October 21, 2026**



1:15 – 2:15 PM EDT




Metro Toronto Convention Center, Lecture Hall 718

This non-CE activity is provided by Sanofi. This independent presentation is not included in the MSToronto2026 accredited program. MSToronto2026 registration is required to attend this independent Industry Supported Satellite Symposium. This is a non-promotional medical symposium sponsored by Sanofi. The content was developed by Sanofi in consultation with scientific experts for scientific exchange purposes and is not eligible for CME credits. This event is for HCPs only. Speakers will receive compensation for their participation in this event.

©2026 Sanofi. All rights reserved. 450 Water Street, Cambridge, MA 02141.

MAT-GLB-2604695- 1.0 – 10/2026

sanofi

A microscopic image of neurons, showing their cell bodies and branching processes. The image is overlaid with a semi-transparent purple filter. The text is positioned in the upper half of the image, with the word 'sanofi' in the bottom right corner.

This symposium, led by **Drs. Amit Bar-Or, Jennifer Gommerman, and Ann Bass**, will explore **persistent unmet needs in multiple sclerosis and the immune network interactions** that drive the disease. The faculty will examine the involvement of both adaptive and innate immunity, the **role of central nervous system border tissues** in compartmentalized neuroinflammation, and the potential importance of **targeting immune network dysregulation** to address both acute and chronic neuroinflammation in multiple sclerosis.

CE, continuing education; CME, continuing medical education; CNS, central nervous system; EDT, Eastern Daylight Time; FAAN, Fellow of the American Academy of Neurology; FANA, Fellow of the American Neurological Association; FRCP, Fellow of the Royal College of Physicians; HCP, healthcare professional; MS, multiple sclerosis.

sanofi

AGENDA

- The involvement of both adaptive and innate immunity
- The role of CNS border tissues in CNS compartmentalized neuroinflammation
- The importance of targeting immune network dysregulation to potentially address both acute and chronic neuroinflammation in MS
- Live Q&A



AMIT BAR-OR

MD, FRCP, FAAN, FANA



JEN GOMMERMAN

PhD



ANN BASS

MD

sanofi



AMIT BAR-OR

MD, FRCP, FAAN, FANA

*University of Pennsylvania and Children's
Hospital of Philadelphia, Philadelphia, PA, USA*

Dr. Amit Bar-Or holds the Melissa and Paul Anderson President's Distinguished Chair at the University of Pennsylvania, where he directs the Center for Neuroinflammation and Experimental Therapeutics and serves as chief of the Division of Multiple Sclerosis and Related Disorders. He is cross-appointed at Children's Hospital of Philadelphia and co-directs an age-span program that supports continuity of care, education, and research from childhood through adulthood.

His research focuses on neuroimmune health and inflammatory diseases of the central nervous system across the age span. His laboratory studies immune regulation, immune–neural interactions, biomarkers, experimental therapies, and precision-medicine strategies for autoimmune and CNS inflammatory diseases. He has published more than 400 peer-reviewed articles and has led national and international research collaborations.

Dr. Bar-Or earned his medical degree at McGill University and completed postgraduate training at Massachusetts General Hospital, Harvard Medical School, Brigham and Women's Hospital, the Massachusetts Institute of Technology, and the Harvard School of Public Health. His honors include the 2021 Barancik Prize for Innovation in Multiple Sclerosis Research and the 2025 John Dystel Prize for Multiple Sclerosis Research.

sanofi



JEN GOMMERMAN

PhD

*Temerty Faculty of Medicine,
University of Toronto, Toronto, ON, Canada*

Dr. Jennifer Gommerman is professor and chair of the Department of Immunology at the University of Toronto's Temerty Faculty of Medicine and holds a Canada Research Chair in Tissue-Specific Immunity. Her research examines how members of the tumor necrosis factor superfamily regulate immunity and autoimmunity. Her team has identified a gut-brain axis that regulates neuroinflammation and studies the role of B lymphocytes in people with multiple sclerosis and in animal models of the disease.

Dr. Gommerman earned her PhD in immunology at the University of Toronto in 1998 and completed postdoctoral training at Harvard Medical School, where she studied the complement pathway. She joined Biogen as a staff scientist in 2000 and returned to the University of Toronto as an assistant professor in 2003. She was promoted to professor in 2015 and became department chair in 2023. She has received multiple mentorship awards from the Temerty Faculty of Medicine and was named a Distinguished Fellow of the American Association of Immunologists in 2025.



sanofi



ANN BASS

MD

Lone Star Neurology, San Antonio, TX, USA

Dr. Ann Bass is medical director of the MS Clinic at Lone Star Neurology in San Antonio, where she manages approximately 2,500 patients with multiple sclerosis and related central nervous system demyelinating disorders. She is also an adjunct assistant professor of neurology at the University of Texas Health Science Center at San Antonio, where she earned her medical degree and completed her residency.

Dr. Bass is a principal investigator and steering committee member for numerous MS clinical trials, as well as a frequent author, co-author, and national and international speaker on MS-related topics. She is a member of the Healthcare Advisory Committee for the National Multiple Sclerosis Society's South Central Region and has contributed to legislative efforts to broaden access to MS therapies across Texas. A diplomate of the American Academy of Neurology, she is also an active member of the Texas Neurological Society.



sanofi